ArticleFrontiers in oncology2025

Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer.

Anna R Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.